Broncus Deepens Lung Disease Push as Revenue Plunges on One-Off Hit

Broncus Holding Corp. ( (HK:2216) ) has issued an announcement.

Broncus Holding Corporation reported a sharp downturn in 2025 revenue, largely due to a one-off sales return, which pushed the group into a gross loss and widened its annual loss despite maintaining a sizable cash position. The financial setback comes as the company continues to invest in commercialization and clinical evidence for its core respiratory products, positioning itself for long-term growth in the lung disease treatment market.

During the year, Broncus secured China approval for its BroncAblate transbronchial radiofrequency ablation system for lung cancer, with adoption across more than 20 provinces and use in nearly 200 procedures at over 30 hospitals, and also gained marketing authorization in Hong Kong. Clinical data published in a peer-reviewed journal supported the safety and efficacy of BroncAblate, while the company’s COPD portfolio, including the marketed InterVapor system and BroncTarget in confirmatory trials, expanded its presence to nearly 30 provinces as physicians and patients increasingly recognize the benefits of these minimally invasive therapies.

The most recent analyst rating on (HK:2216) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Broncus Holding Corp. stock, see the HK:2216 Stock Forecast page.

More about Broncus Holding Corp.

Broncus Holding Corporation is a medical device company focused on interventional therapies for lung diseases, including lung cancer and chronic obstructive pulmonary disease. Its core products, such as the BroncAblate transbronchial radiofrequency ablation system and the InterVapor thermal vapor treatment system, target minimally invasive treatment of pulmonary conditions in China and selected overseas markets.

Average Trading Volume: 647,509

Technical Sentiment Signal: Sell

Current Market Cap: HK$608M

See more data about 2216 stock on TipRanks’ Stock Analysis page.